UBS Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-168,059
| Closed | -$1.88M | – | 8421 |
|
|
2017
Q3 | $1.88M | Buy |
168,059
+7,104
| +4% | +$78.4K | ﹤0.01% | 3182 |
|
|
2017
Q2 | $1.77M | Buy |
160,955
+160,879
| +211,683% | +$1.61M | ﹤0.01% | 3129 |
|
|
2017
Q1 | $0 | Sell |
76
-2,284
| -97% | -$22.8K | ﹤0.01% | 8304 |
|
|
2016
Q4 | $26K | Buy |
2,360
+961
| +69% | +$9.61K | ﹤0.01% | 6362 |
|
|
2016
Q3 | $14K | Buy |
1,399
+239
| +21% | +$2.6K | ﹤0.01% | 6582 |
|
|
2016
Q2 | $15K | Sell |
1,160
-4,858
| -81% | -$63.7K | ﹤0.01% | 6543 |
|
|
2016
Q1 | $66K | Buy |
6,018
+3,273
| +119% | +$29.1K | ﹤0.01% | 5287 |
|
|
2015
Q4 | $25K | Buy |
2,745
+34
| +1% | +$285 | ﹤0.01% | 6535 |
|
|
2015
Q3 | $19K | Sell |
2,711
-4,389
| -62% | -$37.6K | ﹤0.01% | 6773 |
|
|
2015
Q2 | $70K | Sell |
7,100
-8,637
| -55% | -$78.7K | ﹤0.01% | 5706 |
|
|
2015
Q1 | $140K | Buy |
15,737
+8,506
| +118% | +$67.8K | ﹤0.01% | 5163 |
|
|
2014
Q4 | $64K | Buy |
+7,231
| New | +$58.5K | ﹤0.01% | 6192 |
|
UBS Group's SCLN Position: Q4 2017 in Review
UBS Group sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 168,059 shares — an estimated $1.88M sold.
UBS Group first reported a position in SCLN in Q4 2014 and held it in 12 quarters. The position peaked at $1.88M in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- UBS Group reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- UBS Group sold 168,059 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $1.88M.
- UBS Group first reported a position in Sciclone Pharmaceuticals Inc in Q4 2014 and held it in 12 quarters.
- UBS Group's Sciclone Pharmaceuticals Inc position peaked at $1.88M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on UBS Group's 13F filing for Q4 2017, filed 14 Feb 2018.